Treatment Of Endodermal Sinus Tumor Research Articles

A Case of Osteosarcoma after Treatment of Endodermal Sinus Tumor

A Case of Osteosarcoma after Treatment of Endodermal Sinus Tumor

The clinical features and treatment of endodermal sinus tumor of vagina

The clinical features and treatment of endodermal sinus tumor of vagina

Hemolytic Uremic Syndrome Presenting After Treatment of Endodermal Sinus Tumor

Hemolytic uremic syndrome is a rare multisystem disorder that is caused by infections, preeclampsia, autoimmune disorders, or oral contraceptive agents, and rarely in association with different cancers and chemotherapeutic agents. A 34-year-old woman who presented for evaluation of a pelvic mass received a diagnosis of International Federation of Gynecology and Obstetrics (FIGO) stage 1c endodermal sinus tumor at laparotomy. Three months after receiving 3 courses of bleomycin, etoposide, and cisplatinum, she presented with renal failure, thrombocytopenia, anemia, and severe hypertension. Cancer-associated hemolytic uremic syndrome was diagnosed, and the patient was treated with plasmaphoresis, blood transfusion, and hemodialysis. Cancer-associated hemolytic uremic syndrome has a high mortality rate; thus, prompt diagnosis is critical to survival.

Treatment of endodermal sinus tumor in children using a regimen that lacks bleomycin

The EPO-VAC protocol was initiated to study 1) the efficacy of adding a cisplatin regimen (EPO) to VAC alone (the previous standard of care) and 2) the effect of replacing bleomycin with etoposide in the treatment of pediatric endodermal sinus tumors. The eligibility requirements for entry included age <21 years at diagnosis, diagnosis of a primary gonadal or extragonadal tumor (excluding central nervous system tumors and stage I testicular tumors), and histological confirmation of endodermal sinus tumor. Children who met the eligibility criteria were treated with four courses of EPO (etoposide, cisplatin, vincristine) alternating with three courses of VAC (vincristine, dactinomycin, and cyclophosphamide). Eleven children were entered on the protocol. Six patients had extragonadal disease, five patients had ovarian primaries. Seven patients had low-stage tumor (I or II) and four had advanced-stage tumor (III or IV). Three of six evaluable patients attained a complete response at 21 weeks. Three patients with a residual soft tissue mass at restaging underwent further therapy. No patient has relapsed after a median of 51 (range 14-88) months of follow-up. The results of this protocol suggests that a cisplatin-containing regimen that lacks bleomycin is active in childhood endodermal sinus tumors.

Pregnancy following treatment of endodermal sinus tumor of the ovary with combination chemotherapy, including cis-platinum

A 16-year-old woman with endodermal sinus tumor of the ovary underwent conservative surgical debulking and combination chemotherapy and had a recurrence documented by a rise in α-fetoprotein. She had a complete response to a second chemotherapy regimen, including cis-platinum. Subsequently, she became pregnant. The case emphasizes the management of endodermal sinus tumor, including conservative surgery, combination chemotherapy, and monitoring serum α-fetoprotein levels. This is the second report of pregnancy following cis-platinum administration.

Treatment of Endodermal Sinus Tumor in 8 Children

Treatment of Endodermal Sinus Tumor in 8 Children